Centene just reported Q3 2026 and the market barely flinched. The stock rose about 1% to US$68.71 even as the company posted a small loss on basic earnings per share and modest net income pressure for the quarter. The headline was somewhere else entirely. Management lifted full year adjusted EPS guidance to more than US$5.20, leaning hard into a margin story that now runs straight through Medicare and the health benefit ratio.

That gap between a muted one day price move and a guidance upgrade puts sentiment on trial. Traders reacted as if this was a routine print. The fundamentals, especially around profitability targets, tell a much sharper story that the market now has to decide whether to trust.

Love Centene’s higher EPS guidance…